To identify a novel synthetic lethal target in SMARCB1-deficient cancers, we first established an isogenic cell line model by introducing SMARCB1 cDNA into SMARCB1-deficient JMU-RTK-2 rhabdoid tumor cells (Fig. 1a). The gene discussed is SMARCB1; the disease is neoplasm.